4,900
Participants
Start Date
November 17, 2021
Primary Completion Date
January 20, 2023
Study Completion Date
March 28, 2023
One dose of quadrivalent influenza virus split vaccine was administered
"Safety observation: All 4900 vaccine recipients participated in the safety observation after vaccination, and were followed up for adverse events (AE) within 30 minutes and 0-30 days after vaccination, and SAEs within 6 months after vaccination.~In addition to 1050 recipients aged 18-59 years who were included in the first layer test, 350 recipients aged 3-17 years and 350 recipients aged ≥60 years were randomly selected from each group. Blood samples were collected before and 30 days after vaccination for influenza virus HI antibody detection."
Kou Zengqiang, Jinan
Hualan Biological Bacterin Co. Ltd.
INDUSTRY